obesity

R&D

At LSX 2025, editor-in-chief Jonah Comstock connected with Dr Steffen Sebastian-Bolz, chief science officer at Aphaia Pharma.

News

European doctors have said GLP-1 drugs are so effective in obesity that they should be the first choice drug treatment in almost all cases.

R&D

In LSX's Obesity Science and Innovation forum, experts gave the inside scoop on the challenges and opportunities that remain in GLP-1s.

News

Pfizer's answer to a string of disappointing projects in obesity R&D? Bolt on a promising pipeline from another developer.

News

Closed Loop Medicine has launched its first product in the US, a digital tool for personalising the dose of GLP-1 weight-loss therapies.

News

Novo Nordisk has trumpeted data showing oral Wegovy matched the injectable version in a phase 3 trial, ramping up pressure on rival Eli Lilly.